|1.||Zheng, Ke: 1 article (10/2003)|
|2.||Guo, Bao-jing: 1 article (10/2003)|
|3.||Han, Ling: 1 article (10/2003)|
|4.||Jin, Mei: 1 article (10/2003)|
|5.||Wang, Xiao-fang: 1 article (10/2003)|
|6.||Ding, Wen-hong: 1 article (10/2003)|
|7.||Marrouche, Nassir: 1 article (01/2003)|
|8.||Girod, John P: 1 article (01/2003)|
|9.||Natale, Andrea: 1 article (01/2003)|
|10.||Chen, Michael S: 1 article (01/2003)|
04/01/1986 - "Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation."
07/01/1990 - "Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. "
07/01/1986 - "To evaluate the hemodynamic effects of moricizine, 20 patients with frequent nonsustained ventricular tachycardia (VT) with a mean left ventricular ejection fraction (EF) of 39 +/- 14% were enrolled in a prospective single-blind, placebo-controlled study. "
04/01/1984 - "Ten patients with recurrent episodes of ventricular tachycardia (VT) had electrophysiologic studies in the basal state and on chronic oral ethmozin (12.1 +/- 0.6 SE mg/kg/day). "
01/01/2003 - "Moricizine, 200 mg three times daily, was initiated and controlled the ventricular tachycardia. "
|2.||Ventricular Premature Complexes (Premature Ventricular Contraction)
12/01/1989 - "To examine the natural history of long-term anti-arrhythmic therapy in patients with benign and potentially lethal ventricular premature complexes (VPCs), 28 patients with initial efficacy with moricizine (greater than 75% suppression of baseline mean VPCs/hr and greater than 90% suppression of repetitive VPCs) were prospectively followed for 1 to 56 (mean +/- standard deviation 25 +/- 17) months. "
06/01/1991 - "Signal-averaged and standard electrocardiograms (ECGs) were used to monitor moricizine's myocardial effects in 16 patients with frequent ventricular premature complexes taking 600 to 900 mg daily. "
01/01/1989 - "Intravenous ethmozin in a dose of 270-730 mg for 4 h had pronounced antiarrhythmic effect in 80% of patients with frequent ventricular extrasystoles. "
04/15/1986 - "Twenty patients with an average of more than 30 ventricular premature complexes (VPCs) per hour were treated with ethmozine. "
04/15/1986 - "Ethmozine for ventricular premature complexes."
|3.||Cardiac Arrhythmias (Arrythmia)
12/01/1985 - "There was no statistically significant difference between the two dosing regimens for ventricular arrhythmia control with the first day of moricizine dosing; however, when averaging the sixth and seventh days on drug, there was a significantly greater reduction in frequency on the every 12 hour regimen compared to the every 8 hour regimen (p = 0.004). "
01/01/1982 - "The sum total of the results and also the preliminary data on the high antiarrhythmic activity of DAA ethmozine justifies the conclusion that this drug may prove to be effective in the treatment of cardiac arrhythmias."
12/01/1994 - "Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II)."
04/01/1992 - "The Cardiac Arrhythmia Suppression Trial-II was subsequently terminated prematurely because 1) patients treated with moricizine had an excessive cardiac mortality rate during the 1st 2 weeks of exposure to the drug, and 2) there appeared to be little chance of showing a long-term survival benefit from treatment with moricizine. "
06/01/1991 - "The mechanism of action of moricizine, a new antiarrhythmic agent used in the Cardiac Arrhythmia Suppression Trial, is incompletely characterized. "
07/01/1990 - "Preliminary findings have indicated that moricizine is also effective in suppressing atrial ectopic activity, atrioventricular nodal re-entry tachycardia and Wolff-Parkinson-White tachycardias involving accessory pathways. "
10/01/1995 - "Because of the paroxysmal nature of the tachycardias, decreases in patient heart rate could not be correlated with moricizine blood level. "
09/01/1993 - "Electrophysiological evaluation of moricizine in patients with sustained ventricular tachyarrhythmias: low efficacy and high incidence of proarrhythmia."
08/01/1992 - "In conclusion, moricizine has the same significant preventive effect on reperfusion induced ventricular tachyarrhythmias as DSP and MXT."
10/16/1987 - "Intravenous moricizine HCl terminated and prevented tachycardia in 72% and 68% of the patients, respectively. "
|5.||Heart Diseases (Heart Disease)
03/01/1988 - "[Quantitative assessment of the effect of ethmozine and ethacizine on the interval-force relationship in myocardial biopsy material from patients with heart disease]."
05/01/1987 - "Problems in studying pharmacokinetic interactions with digoxin were evaluated using as a test model the examination of a possible interaction between digoxin and ethmozine in a group of 11 patients with cardiac disease. "
10/01/1992 - "No significant difference between the two groups was found in respect to age, arrhythmia at presentation, underlying heart disease, moricizine dose, or concomitant drug therapy."
04/01/1991 - "A randomised, double-blind, crossover trial with Disopyramide 600 mg/day after a placebo period in 10 patients with ventricular extrasystoles, half of whom had underlying cardiac disease, showed that moricizine 750 mg/day significantly reduced (p less than 0.05) the overall number of ventricular extrasystoles by 81 +/- 46% (disopyramide 72 +/- 69%; NS) and that this drug is effective in 2/3 of patients by suppressing 70 to 100% of ventricular extrasystoles, whereas disopyramide was effective in only 40% of the same patients and never gave better results than Moricizine. "
|2.||Drug Therapy (Chemotherapy)
|5.||Electric Countershock (Cardioversion)